Cosentyx (secukinumab) is a biologic medication that is approved for the treatment of several autoimmune conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by blocking a specific protein in the immune system that is responsible for inflammation. The safety of Cosentyx in elderly patients has been studied, and the available evidence suggests that it is generally well-tolerated.
According to DrugPatentWatch [1], Cosentyx was first approved by the FDA in 2015 and has since been used by thousands of patients. The drug's safety profile has been extensively studied in clinical trials, including studies that specifically included elderly patients. The prescribing information for Cosentyx states that there were no significant differences in the safety and efficacy of the drug between patients aged 65 and older and younger patients.
A study published in the journal Acta Dermato-Venereologica [3] evaluated the safety and efficacy of Cosentyx in elderly patients with psoriasis. The study included 93 patients aged 65 years and older who were treated with Cosentyx for up to 52 weeks. The researchers found that the drug was well-tolerated, with no significant safety concerns identified. The study also showed that Cosentyx was effective in improving psoriasis symptoms in elderly patients.
Another study published in the journal Clinical Rheumatology [2] evaluated the safety and efficacy of Cosentyx in elderly patients with psoriatic arthritis. The study included 43 patients aged 65 years and older who were treated with Cosentyx for up to 52 weeks. The researchers found that the drug was well-tolerated, with no significant safety concerns identified. The study also showed that Cosentyx was effective in improving psoriatic arthritis symptoms in elderly patients.
In conclusion, the available evidence suggests that Cosentyx is generally safe and well-tolerated in elderly patients. Clinical trials have shown that the drug is effective in improving symptoms of psoriasis and psoriatic arthritis in this population. However, as with any medication, individual patients may experience side effects or have other factors that could affect their response to treatment. Therefore, it is important for elderly patients to discuss the risks and benefits of Cosentyx with their healthcare provider before starting treatment.
Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847154/
[3] https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3678.